Sarilumab, an IL6-R antagonist, is approved for the treatment of adult patients with moderate-to-severe RA with an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs) [20–22]. The gene discussed is IL6R; the disease is rheumatoid arthritis.